ABUS vs MKTX · P/E 5.4, rev $6.2M vs P/E 13, rev $817.1M
Arbutus Biopharma Corp (ABUS) versus MarketAxess Holdings Inc (MKTX) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
MarketAxess Holdings Inc (MKTX) is a capital markets company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported MKTX revenue for 2024-12-31 was $817.1M. Net income was $274.2M. Revenue was up 8.6% from 2023-12-31 to 2024-12-31. MKTX currently screens at market cap $4.00B and trailing P/E 13.3.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. MKTX currently screens at market cap $4.00B and trailing P/E 13.3.
Not investment advice. Open the ABUS and MKTX stock pages for the full models.
Not investment advice.